Date published: 2026-9-6

1-800-457-3801

SCBT Portrait Logo
Seach Input

Ribosomal Protein S19 CRISPR Activation Plasmid (h): sc-402405-ACT

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: human
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • Ribosomal Protein S19 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
  • Ribosomal Protein S19 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
  • The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
  • gRNAs encoded by Ribosomal Protein S19 CRISPR Activation Plasmid (h) and Ribosomal Protein S19 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the RPS19 transcriptional start site. One or both designs may be available
  • Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Ribosomal Protein S19 Antibody (WW-4): sc-100836
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    Ribosomal Protein S19 CRISPR Activation Plasmid (h)

    sc-402405-ACT
    20 µg
    $397.00

    Ribosomal Protein S19 CRISPR Activation Plasmid (h2)

    sc-402405-ACT-2
    20 µg
    $397.00

    RPS19 encodes ribosomal protein S19, an essential component of the 40S small ribosomal subunit that supports ribosome biogenesis and accurate translation initiation. Beyond its structural role in the ribosome, RPS19 contributes to nucleolar maturation of pre-rRNA and integrates with cellular proteostasis and stress-response programs that couple protein synthesis to growth control. Perturbation of RPS19 function disrupts erythroid differentiation and is strongly associated with Diamond–Blackfan anemia and ribosomopathy-linked p53-dependent stress signaling. As a core housekeeping gene, RPS19 expression is also used to probe translational capacity, nucleolar function, and adaptation to metabolic or genotoxic stress in human cell models.

    Ribosomal Protein S19 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous RPS19 expression without altering the underlying DNA sequence.

    Ribosomal Protein S19 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the RPS19 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.

    Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the RPS19 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Ribosomal Protein S19 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native RPS19 locus and enabling the study of Ribosomal Protein S19-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Ribosomal Protein S19 pathway restoration in tumor cells with silenced or reduced RPS19 expression.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.